S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Cotinga Pharmaceuticals Stock Price, News & Analysis (CVE:COT)

Today's Range N/A
50-Day Range
C$0.12
MA: C$0.14
C$0.20
52-Week Range N/A
Volume400 shs
Average Volume41,935 shs
Market CapitalizationC$2.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-519-8585157

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC($0.11) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$2.86 million
Next Earnings Date10/21/2019 (Estimated)
OptionableOptionable

Receive COT News and Ratings via Email

Sign-up to receive the latest news and ratings for COT and its competitors with MarketBeat's FREE daily newsletter.


Cotinga Pharmaceuticals (CVE:COT) Frequently Asked Questions

What is Cotinga Pharmaceuticals' stock symbol?

Cotinga Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "COT."

How were Cotinga Pharmaceuticals' earnings last quarter?

Cotinga Pharmaceuticals Inc (CVE:COT) announced its earnings results on Wednesday, September, 4th. The company reported ($0.04) earnings per share for the quarter. View Cotinga Pharmaceuticals' Earnings History.

When is Cotinga Pharmaceuticals' next earnings date?

Cotinga Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October 21st 2019. View Earnings Estimates for Cotinga Pharmaceuticals.

Has Cotinga Pharmaceuticals been receiving favorable news coverage?

News headlines about COT stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cotinga Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cotinga Pharmaceuticals.

Who are some of Cotinga Pharmaceuticals' key competitors?

What other stocks do shareholders of Cotinga Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals investors own include Aurora Cannabis (ACB), Cascades (CAS), InPlay Oil (IPO), Exchange Income (EIF), Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Canadian National Railway (CNI), Harvest One Cannabis (HVT), Datametrex AI (DM) and American Manganese (AMY).

Who are Cotinga Pharmaceuticals' key executives?

Cotinga Pharmaceuticals' management team includes the folowing people:
  • Ms. Alison D. Silva, CEO, Pres & Director
  • Dr. Richard T. Ho, Chief Scientific Officer (Age 56)
  • Mr. Victor Hugo, Chief Financial Officer (Age 51)
  • Ms. Debi Sanderson MBA, Director of Resourcing & Operations
  • Mr. Paul Papi, VP of Investor Relations

How do I buy shares of Cotinga Pharmaceuticals?

Shares of COT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals has a market capitalization of C$0.00. View Additional Information About Cotinga Pharmaceuticals.

What is Cotinga Pharmaceuticals' official website?

The official website for Cotinga Pharmaceuticals is http://cotingapharma.com/.

How can I contact Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals' mailing address is 100 Collip Cir Suite 230B, LONDON, ON N6G 4X8, Canada. The company can be reached via phone at +1-519-8585157.


MarketBeat Community Rating for Cotinga Pharmaceuticals (CVE COT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Cotinga Pharmaceuticals and other stocks. Vote "Outperform" if you believe COT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel